CoChat

Low incidence of anti‐drug antibodies in patients with type 2 diabetes treated with once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide

Milicevic, Z., Anglin, G., Harper, K., Konrad, R. J., Skrivanek, Z., Glaesner, W., Karanikas, C. A., Mace, K. · 2016 · Diabetes, Obesity and Metabolism
Cited by 32

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Therapeutic administration of peptides may result in anti‐drug antibody ( ADA ) formation, hypersensitivity adverse events ( AEs ) and reduced efficacy. As a large peptide, the immunogenicity of once‐weekly glucagon‐like peptide‐1 ( GLP ‐1) receptor agonist dulaglutide is of considerable interest. The present study assessed the incidence of treatment‐emergent dulaglutide ADAs , hypersensitivity AEs , injection site reactions ( ISRs ), and glycaemic control in ADA ‐positive patients in nine phase II and phase III trials (dulaglutide, N = 4006; exenatide, N = 276; non‐ GLP ‐1 comparators, N = 1141). Treatment‐emergent dulaglutide ADAs were detected using a solid‐phase extraction acid dissociation binding assay. Neutralizing ADAs were detected using a cell‐based assay derived from human endothelial kidney cells ( HEK293 ). A total of 64 dulaglutide‐treated patients (1.6% of the population) tested ADA ‐positive versus eight (0.7%) from the non‐ GLP ‐1 comparator group. Of these 64 patients, 34 (0.9%) had dulaglutide‐neutralizing ADAs , 36 (0.9%) had native‐sequence GLP ‐1 ( nsGLP ‐1) cross‐reactive ADAs and four (0.1%) had nsGLP ‐1 neutralization ADAs . The incidence of hypersensitivity AEs and ISRs was similar in the dulaglutide versus placebo groups. No dulaglutide ADA ‐positive patient reported hypersensitivity AEs . Because of the low incidence of ADAs , it was not possible to establish their effect on glycaemic control.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12640

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 32

Metadata

Authors
Milicevic, Z., Anglin, G., Harper, K., Konrad, R. J., Skrivanek, Z., Glaesner, W., Karanikas, C. A., & Mace, K.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2016-03-04
Volume
18
Issue
5
Pages
533-536
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2335878298
Cited by
32
References
3
FWCI
4.04
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Low incidence of anti‐drug antibodies in patients with type 2 diabetes treated with once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide. https://app.cochat.ai/papers/10.1111/dom.12640
The paper
Milicevic, Z., Anglin, G., Harper, K., Konrad, R. J., Skrivanek, Z., Glaesner, W., Karanikas, C. A., & Mace, K. (2016). Low incidence of anti‐drug antibodies in patients with type 2 diabetes treated with once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12640

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.